Alessandra Fabi

Summary

Country: Italy

Publications

  1. ncbi request reprint Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer
    Umberto Pacetti
    Operative Unit of Oncology, A Fiorini Hospital, Terracina, Italy
    Anticancer Res 33:1721-4. 2013
  2. doi request reprint An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting
    Alessandra Fabi
    Regina Elena National Cancer Institute, Division of Medical Oncology, Via Elio Chianesi, 53 00144, Rome, Italy
    Expert Opin Pharmacother 14:629-41. 2013
  3. pmc Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, Italy
    BMC Cancer 12:482. 2012
  4. ncbi request reprint New target therapies for brain metastases from breast cancer
    G Metro
    Division of Medical Oncology, Santa Maria della Misericordia Azienda Ospedaliera di Perugia via Dottori, Perugia, Italy
    Curr Cancer Drug Targets 12:210-7. 2012
  5. ncbi request reprint Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena National Cancer Institute, via Elio Chianesi 52, 00144 Rome, Italy
    Support Care Cancer 11:156-61. 2003
  6. doi request reprint Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi, 53, Rome, Italy
    J Neurooncol 100:209-15. 2010
  7. doi request reprint Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Breast 17:499-505. 2008
  8. doi request reprint Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Support Care Cancer 16:1375-80. 2008
  9. doi request reprint Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Oncology 78:141-9. 2010
  10. ncbi request reprint Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Cancer Chemother Pharmacol 57:615-23. 2006

Detail Information

Publications81

  1. ncbi request reprint Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer
    Umberto Pacetti
    Operative Unit of Oncology, A Fiorini Hospital, Terracina, Italy
    Anticancer Res 33:1721-4. 2013
    ..To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer...
  2. doi request reprint An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting
    Alessandra Fabi
    Regina Elena National Cancer Institute, Division of Medical Oncology, Via Elio Chianesi, 53 00144, Rome, Italy
    Expert Opin Pharmacother 14:629-41. 2013
    ..These pharmacological properties have resulted in improved antiemetic activity in clinical trials, particularly in the treatment of delayed CINV following moderate emetogenic chemotherapy (MEC)...
  3. pmc Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, Italy
    BMC Cancer 12:482. 2012
    ..Although preclinical results that anti-angiogenic agents combined with hormonal therapy (HT) could be active, no clinical data exist about combination of maintenance Bevacizumab (mBev) with HT...
  4. ncbi request reprint New target therapies for brain metastases from breast cancer
    G Metro
    Division of Medical Oncology, Santa Maria della Misericordia Azienda Ospedaliera di Perugia via Dottori, Perugia, Italy
    Curr Cancer Drug Targets 12:210-7. 2012
    ....
  5. ncbi request reprint Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena National Cancer Institute, via Elio Chianesi 52, 00144 Rome, Italy
    Support Care Cancer 11:156-61. 2003
    ..Correct prophylaxis is necessary when HEC is given, and antiemetic protection for patients receiving MEC must be improved; among patients treated with LEC those at high risk must be identified so that overtreatment can be avoided...
  6. doi request reprint Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi, 53, Rome, Italy
    J Neurooncol 100:209-15. 2010
    ..The role of MGMT gene promoter methylation status in relation to sensitivity to fotemustine is still unclear and needs further evaluation in future clinical trials...
  7. doi request reprint Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Breast 17:499-505. 2008
    ..The corresponding values for CB were 77.6% and 42.6%, respectively. A second trastuzumab-containing regimen beyond progression yields a considerable rate of OR and CB in HER-2 + MBC patients. Randomized trials are warranted...
  8. doi request reprint Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Support Care Cancer 16:1375-80. 2008
    ..In the present phase II randomized study, two different schedules of ondansetron were investigated as rescue antiemetic treatment for delayed emesis related to moderately emetogenic chemotherapy (MEC)...
  9. doi request reprint Clinical significance of PTEN and p-Akt co-expression in HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Oncology 78:141-9. 2010
    ..We investigated the clinical impact of the expression of PTEN, p-Akt and PI3K in HER2-positive metastatic breast cancer (MBC) patients treated with trastuzumab-based therapies...
  10. ncbi request reprint Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Cancer Chemother Pharmacol 57:615-23. 2006
    ....
  11. ncbi request reprint Bone metastasis from glioblastoma multiforme without central nervous system relapse: a case report
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Anticancer Res 24:2563-5. 2004
    ..We report the case of a man affected by a glioblastoma who had a lumbar spine metastases without any brain relapse after excision of cerebral glioblastoma multiforme and brain radiotherapy...
  12. ncbi request reprint Epirubicin plus docetaxel in metastatic breast cancer: escalating dose does not improve efficacy. A phase II study
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Anticancer Res 24:1963-7. 2004
    ....
  13. ncbi request reprint Choroid plexus carcinoma in the adult: is there a role for chemotherapy?
    A Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 24:493-6. 2005
    ..We report a rare case of an adult woman affected by a choroid plexus tumour and a discussion on the therapeutic management of this uncommon adult malignancy...
  14. ncbi request reprint The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study
    A Fabi
    Dept of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 23:25-32. 2004
    ..The survival results were interesting: the median survival time was 14 months (9-19 months) and the 1- and 2-year survival was 59% and 16%, respectively...
  15. pmc Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    BMC Cancer 9:101. 2009
    ..Also, the impact of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status on fotemustine activity has never been explored in the clinical setting...
  16. ncbi request reprint Pseudoprogression and MGMT status in glioblastoma patients: implications in clinical practice
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena Cancer Institute, 00144 Rome, Italy
    Anticancer Res 29:2607-10. 2009
    ..The PsPD phenomenon opens the prospect of a new era for the management of glioblastoma patients undergoing radio-chemotherapy...
  17. ncbi request reprint Bone and lung metastases from intracranial meningioma
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Anticancer Res 26:3835-7. 2006
    ..According to these sites of metastases, it is suggested that in patients with a history of relapsed meningioma, a total body CT scan should be performed in order to investigate other possible sites of disease...
  18. ncbi request reprint Retroperitoneal liposarcoma with metastasis to both orbits: an unusual metastatic site
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Anticancer Res 25:4769-71. 2005
    ..Our report is a new case and the appropriate methods for diagnosis and treatment of this unusual metastatic site in this type of cancer are discussed...
  19. doi request reprint Time to first tumor progression as outcome predictor of a second trasuzumab-based therapy beyond progression in HER-2 positive metastatic breast cancer
    Giulio Metro
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Breast J 16:66-72. 2010
    ..In the clinic, time to first tumor progression may represent a useful tool to identify patients who are more likely to benefit from trastuzumab beyond progression...
  20. ncbi request reprint Aromatase inhibitors in post-menopausal metastatic breast carcinoma
    Paolo Carlini
    Regina Elena Cancer Institute, Division of Medical Oncology A, Rome, Italy
    Expert Opin Investig Drugs 16:1023-36. 2007
    ..In the metastatic setting, results are limited and are based on retrospective analyses...
  21. ncbi request reprint New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma: a pooled analysis of the randomized trials
    Paolo Carlini
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer 104:1335-42. 2005
    ....
  22. ncbi request reprint Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide
    Paola Papaldo
    Division of Medical Oncology, Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    J Clin Oncol 23:6908-18. 2005
    ....
  23. ncbi request reprint HER-2-positive metastatic breast cancer: trastuzumab and beyond
    Giulio Metro
    Regina Elena Cancer Institute, Division of Medical Oncology A, Via Elio Chianesi, 53, 00144 Rome, Italy
    Expert Opin Pharmacother 9:2583-601. 2008
    ....
  24. doi request reprint Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme
    Giulio Metro
    Division of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer Chemother Pharmacol 65:391-7. 2010
    ..In order to evaluate the activity of gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme (GBM), a prospective single-center phase II study was conducted...
  25. ncbi request reprint Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation
    Alessandra Fabi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    Cancer Chemother Pharmacol 62:717-25. 2008
    ....
  26. ncbi request reprint Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: pooled-analysis of 8794 patients
    Emilio Bria
    Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Roma, Italy
    Cancer Treat Rev 32:325-32. 2006
    ..We performed a literature-based meta-analysis, to look how much advantages adjuvant the "early switch" strategy add over standard tamoxifen for 5 years...
  27. doi request reprint Quality of life and seizure control in patients with brain tumor-related epilepsy treated with levetiracetam monotherapy: preliminary data of an open-label study
    Loredana Dinapoli
    Department of Neuroscience and Cervical Facial Pathology, Center for Tumor related Epilepsy, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, 00144, Rome, Italy
    Neurol Sci 30:353-9. 2009
    ..Levetiracetam caused mild and reversible side effects. These preliminary data on LEV monotherapy in patients with brain tumor-related epilepsy show that this antiepileptic drug is efficacious and well tolerated...
  28. ncbi request reprint Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: towards optimization of association and schedule
    Giulio Metro
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Rome, Italy
    Anticancer Res 28:1245-58. 2008
    ....
  29. pmc A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study
    Flavia Novelli
    Pathology Department, Regina Elena Cancer Institute, Rome, Italy
    Breast Cancer Res 10:R74. 2008
    ..In particular, there are no data concerning ER-beta distribution within the novel molecular breast cancer subtypes luminal A (LA) and luminal B (LB), HER2 (HS), and triple-negative (TN)...
  30. doi request reprint Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer
    Alessandra Fabi
    Regina Elena National Cancer Institute, Department of Oncology A, Via Elio Chianesi, 53, 00144 Rome, Italy
    Expert Opin Pharmacother 14:699-706. 2013
    ..It is aimed to evaluate novel biomarkers predictive of lapatinib response, we analyzed EGFR protein and gene status in a series of 50 metastatic HER2-positive BC patients...
  31. ncbi request reprint Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
    Paola Papaldo
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Breast 15:269-72. 2006
    ..The potential of combining anthracyclines and endocrine therapies is reviewed and discussed...
  32. ncbi request reprint Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study
    Alessandra Fabi
    Division of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    J Neurooncol 87:79-84. 2008
    ..Thus, fixed dose-rate gemcitabine at 175 mg/m(2)/weekly is the recommended regimen for further evaluation in a phase II study that is presently in progress...
  33. ncbi request reprint Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?
    Gianluigi Ferretti
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Chest 130:1808-16. 2006
    ..To evaluate whether the incidence of recurrent venous thromboembolism (VTE) events after therapy differs for patients treated with long-term low-molecular-weight heparin (LMWH) or oral anticoagulant therapy (OAT)...
  34. doi request reprint Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease
    Stefano Telera
    Division of Neurosurgery, Istituto Nazionale Tumori Regina Elena, Via Elio Chianesi 53, 00144, Rome, Italy
    J Neurooncol 113:313-25. 2013
    ....
  35. pmc Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
    Federica Cuppone
    Department of Medical Oncology, Regina Elena National Cancer Institute, Roma, Italy
    J Exp Clin Cancer Res 30:54. 2011
    ..Although the addition of bevacizumab significantly improves the efficacy of chemotherapy for advanced breast cancer, regulatory concerns still exist with regard to the magnitude of the benefits and the overall safety profile...
  36. doi request reprint Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines
    Patrizia Vici
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer Chemother Pharmacol 67:687-93. 2011
    ..In the present phase I/II trial, we investigated the association of FDR GEM plus PACL...
  37. doi request reprint Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study
    Antonio Rozzi
    Clinical Oncology Unit, Istituto Neurotraumatologico Italiano, Grottaferrata, Rome, Italy
    Support Care Cancer 19:697-701. 2011
    ..The aim of the present study was to investigate the efficacy of palonosetron for prevention of CINV-induced by adjuvant TMZ...
  38. ncbi request reprint Alfa-epoietin and anaemia in gynaecological cancer
    Barbara Di Cocco
    Division of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Anticancer Res 24:1287-92. 2004
    ..In this review we discuss the role of alfa-epoetin in the management of gynaecological and breast cancers...
  39. doi request reprint Perfusion Computed Tomography (PCT) adopting different perfusion metrics: recurrence of brain metastasis or radiation necrosis?
    Antonello Vidiri
    Radiology and Diagnostic Imaging Department, Istituto Regina Elena, Via Elio Chianesi 53, 00144 Rome, Italy
    Eur J Radiol 81:1246-52. 2012
    ....
  40. ncbi request reprint Clinical evaluation of the use of exemestane as further hormonal therapy after nonsteroidal aromatase inhibitors in postmenopausal metastatic breast cancer patients
    Paolo Carlini
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Cancer Invest 25:102-5. 2007
    ..Few clinical data are published on the sequential use of different classes of aromatase inhibitors...
  41. ncbi request reprint HER2/neu role in breast cancer: from a prognostic foe to a predictive friend
    Gianluigi Ferretti
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Curr Opin Obstet Gynecol 19:56-62. 2007
    ....
  42. doi request reprint HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care
    Alessandra Fabi
    Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Clin Cancer Res 17:2055-64. 2011
    ..To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be predictive of change in HER2 expression...
  43. pmc Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation
    Antonello Vidiri
    Radiology and Diagnostic Imaging Department, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    J Exp Clin Cancer Res 31:33. 2012
    ....
  44. doi request reprint Metastases to the cerebellum. Results and prognostic factors in a consecutive series of 44 operated patients
    Alfredo Pompili
    Division of Neurosurgery, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome, Italy
    J Neurooncol 88:331-7. 2008
    ..Among the prognostic factors, the cerebellar location was never considered, although this results in hydrocephalus, brain stem compression, ataxia, intracranial hypertension...
  45. ncbi request reprint Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism
    Gianluigi Ferretti
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Thromb Res 119:525-9. 2007
    ..98). Long-term treatment with LMWH does not seem to be significantly safer than OAT. However, no conclusive interpretation from different studies with different designs is possible...
  46. doi request reprint Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy
    Marta Maschio
    Center for Tumor related Epilepsy, Department of Neuroscience and Cervical Facial Pathology, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, 00144 Rome, Italy
    J Neurooncol 90:217-21. 2008
    ..We studied the effect of temozolomide therapy on the disposition of the new antiepileptic drugs topiramate (TPM) or oxcarbazepine (OXC)...
  47. ncbi request reprint Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients
    Gianluigi Ferretti
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Oncology 69:35-43. 2005
    ..To evaluate the modifications of circulating angiogenic factors, metalloproteinases and acute-phase cytokines after the first single zoledronic acid (ZA) intravenous infusion...
  48. ncbi request reprint Nail disorders in a woman treated with ixabepilone for metastatic breast cancer
    Andrea Alimonti
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Anticancer Res 25:3531-2. 2005
    ..Here, we report a case of a 59-year-old woman treated with Ix at 40 mg/m2 day 1 q 21 days who, after 8 cycles of therapy, developed onycholysis and subungual hemorrhagic bullas in the fingernails...
  49. pmc Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome Italy
    J Exp Clin Cancer Res 30:10. 2011
    ..To evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources available at the treating center...
  50. ncbi request reprint Addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide
    Paola Papaldo
    Division of Medical Oncology A, Regina Elena Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    J Clin Oncol 21:3462-8. 2003
    ..Granulocyte colony-stimulating factor (G-CSF) was added to maintain the EC dose-intensity...
  51. ncbi request reprint Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors
    Serena Di Cosimo
    Department of Medical Oncology, University La Sapienza, Rome, Italy
    Drugs Today (Barc) 39:157-74. 2003
    ..However, the available data demonstrate a significant role of lonidamine in modulating anthracycline and platinum compound activity...
  52. ncbi request reprint Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women?
    Paolo Carlini
    Department of Medical Oncology, Regina Elena Cancer Institute, Via Elio Chianesi 53, Rome, Italy
    J Steroid Biochem Mol Biol 86:107-9. 2003
    ....
  53. ncbi request reprint Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life
    Marta Maschio
    Center for Tumor related Epilepsy, Neurology Unit, Department of Neuroscience and Cervical Facial Pathology, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, 00144 Rome, Italy
    J Neurooncol 104:205-14. 2011
    ..Our data indicate that LEV, in patients with BTRE, is safe and efficacious, with positive impact on QoL...
  54. pmc Quantitative analysis of CT-perfusion parameters in the evaluation of brain gliomas and metastases
    Anna Maria Di Nallo
    Regina Elena National Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 28:38. 2009
    ..The perfusion scan provided 11 parametric maps, including Cerebral Blood Volume (CBV), Cerebral Blood Flow (CBF), Average Perfusion (Pmean) and Permeability-surface area product (PS)...
  55. ncbi request reprint Weight of epilepsy in brain tumor patients
    Marta Maschio
    Center for Tumor related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Rome, Italy
    J Neurooncol 118:385-93. 2014
    ..Nevertheless, future studies could be designed with a follow-up period and with a patient stratification in order to better understand the weight of epilepsy for these patients. ..
  56. pmc The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: a comparative study on traditional antiepileptic drugs versus oxcarbazepine
    Marta Maschio
    Center for Tumor related Epilepsy, Department of Neuroscience and Cervical Facial Pathology, National Institute for Cancer Regina Elena, Via Elio Chianesi 53, 00144 Roma, Italy
    J Exp Clin Cancer Res 28:60. 2009
    ..Seizure control doesn't represent the only challenging goal in patients with brain tumor-related epilepsy. Side effects have often taken precedence for patients' quality of life...
  57. pmc Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas
    Valentina Folgiero
    Department of Experimental Oncology, Regina Elena Cancer Institute, Rome, Italy
    PLoS ONE 3:e1592. 2008
    ..We sought to improve understanding of this process in order to provide the involvement of both receptors insight into mechanism of Tamoxifen resistance...
  58. ncbi request reprint Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin
    Anna Ceribelli
    Department of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Cancer 98:337-43. 2003
    ....
  59. ncbi request reprint The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions
    Paola Malaguti
    Department of Medical Oncology, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Anticancer Res 33:21-8. 2013
    ..This review of the literature analyzes the available data emerging from trials and evaluates the efficacy and safety of mTOR inhibitors in all subtypes of breast cancer...
  60. ncbi request reprint Brain radiotherapy during treatment with anticonvulsant therapy as a trigger for toxic epidermal necrolysis
    Giulio Metro
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Anticancer Res 27:1167-9. 2007
    ..Alternatively, discontinuation of antiepileptic treatment before the initiation of brain radiotherapy, or the use of anticonvulsants associated with a lower risk of developing cutaneous reactions might be considered...
  61. doi request reprint Supportive care in neurooncology
    Andrea Pace
    Division of Neurology, Regina Elena Cancer Institute, Rome, Italy
    Curr Opin Oncol 22:621-6. 2010
    ..On the other hand, some important problems such as rehabilitation, depression, psychological support/communication and end-of-life issues/treatment decisions have been poorly investigated so far...
  62. ncbi request reprint Cisplatin and escalating doses of paclitaxel and epirubicin in advanced ovarian cancer. A phase I study
    M Nardi
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Cancer Chemother Pharmacol 48:255-8. 2001
    ..The objectives of this study were to determine both the maximum tolerated dose (MTD) and the antitumor activity of this combination...
  63. ncbi request reprint Chemotherapy in neoplastic meningitis
    Andrea Pace
    Regina Elena National Cancer Institute, Rome, Italy
    Crit Rev Oncol Hematol 60:194-200. 2006
    ..This review summarizes intrathecal and systemic chemotherapeutic options in the treatment of NM and the related toxicities...
  64. ncbi request reprint Testis metastasis as an initial manifestation of an occult gastrointestinal cancer
    Nello Salesi
    Division of Medical Oncology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy
    Anticancer Res 24:1093-6. 2004
    ..In the case of a testicular mass or hydrocele evidence in a patient with an unusual age for primary testis tumor, a diagnosis of metastatic cancer should be considered...
  65. ncbi request reprint Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules
    E Terzoli
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    J Exp Clin Cancer Res 23:207-13. 2004
    ..In conclusion the results of the study showed that dose intensity of vinorelbine could have an improvement in terms of time to progression in pretreated advanced breast cancer...
  66. ncbi request reprint Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic
    Alessandra Fabi
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    J Mol Med (Berl) 92:681-95. 2014
    ....
  67. ncbi request reprint Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
    P Carlini
    Department of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy
    Ann Oncol 12:1539-43. 2001
    ..who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ)...
  68. ncbi request reprint A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease
    P Papaldo
    Division of Medical Oncology A, Regina Elena Cancer Institute, Rome, Italy
    Ann Oncol 17:630-6. 2006
    ....
  69. pmc Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials
    G Ferretti
    Department of Medical Oncology, Regina Elena Cancer Institute, Rome, Italy
    Br J Cancer 94:1789-96. 2006
    ..Investigators should assess heterogeneity of trial results before deriving summary estimates of treatment effect...
  70. pmc In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy
    G Metro
    Medical Oncology, Regina Elena Cancer Institute, via Elio Chianesi 53 00144 Rome, Italy
    Cancer Invest 28:172-80. 2010
    ..They were significantly associated with each other (Spearman's rho > or = .36; p < or = .007). Given their pattern of distribution, RRM1 and BRCA1 are potentially suitable markers for clinical decision making in MBC...
  71. ncbi request reprint Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide for operable HER2-positive breast cancer
    Gianluigi Ferretti
    Oncologist 11:533; author reply 534. 2006
  72. ncbi request reprint Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis
    Gianluigi Ferretti
    Bone 41:155-6. 2007
  73. ncbi request reprint Adjuvant trastuzumab with docetaxel or vinorelbine for HER-2-positive breast cancer
    Gianluigi Ferretti
    Oncologist 11:853-4. 2006
  74. doi request reprint Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer
    Giulio Metro
    Oncologist 12:1467-9; author reply 1469-71. 2007
  75. ncbi request reprint Re: Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer
    Gianluigi Ferretti
    J Natl Cancer Inst 94:1720; author reply 1721-2. 2002
  76. ncbi request reprint HER2/neu expression and hormonal therapy in early breast cancer: can muddy waters become clear?
    Gianluigi Ferretti
    J Clin Oncol 22:568-9. 2004
  77. ncbi request reprint What is the biological significance of circulating blood levels of metalloproteinases?
    Gianluigi Ferretti
    Clin Cancer Res 12:3550-1; author reply 3551. 2006
  78. ncbi request reprint Effect of filgrastim on serum lactate dehydrogenase and alkaline phosphatase values in early breast cancer patients
    Paola Papaldo
    Cancer Invest 22:650-3. 2004
    ....
  79. ncbi request reprint Lumpectomy and tamoxifen alone without additional radiotherapy for women 70 years of age or older with estrogen receptor-positive breast cancer
    Gianluigi Ferretti
    Breast Cancer Res Treat 90:319. 2005
  80. ncbi request reprint Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
    Paolo Carlini
    J Clin Oncol 24:e60-1. 2006
  81. doi request reprint Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha
    Paolo Pedrazzoli
    Divisione di Oncologia Medica Falck, Ospedale Niguarda Ca Granda, Piazza Ospedale Maggiore 20162, Milano, Italy
    J Clin Oncol 26:1619-25. 2008
    ..We have prospectively evaluated whether intravenous iron can increase the proportion of patients with chemotherapy-related anemia who respond to darbepoetin...